EGFR and head and neck squamous cell carcinoma: In this context Bozec et al. demonstrated promising results using the VEGFR inhibitor cediranib (AZD2171) (targeting VEGFR1/2/3) concurrent with the EGFR inhibitor gefitinib and radiotherapy in a VEGF secreting HNSCC xenograft model.